[go: up one dir, main page]

WO2000078934A3 - Use of the ubiquitin specific protease usp25 in the diagnosis and treatment of alzheimer's disease - Google Patents

Use of the ubiquitin specific protease usp25 in the diagnosis and treatment of alzheimer's disease Download PDF

Info

Publication number
WO2000078934A3
WO2000078934A3 PCT/GB2000/002423 GB0002423W WO0078934A3 WO 2000078934 A3 WO2000078934 A3 WO 2000078934A3 GB 0002423 W GB0002423 W GB 0002423W WO 0078934 A3 WO0078934 A3 WO 0078934A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
alzheimer
gene
specific protease
ubiquitin specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/002423
Other languages
French (fr)
Other versions
WO2000078934A2 (en
Inventor
Dean Nizetic
Juergen Groet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9914589.8A external-priority patent/GB9914589D0/en
Priority claimed from GB0008162A external-priority patent/GB0008162D0/en
Application filed by University College London filed Critical University College London
Priority to AU55508/00A priority Critical patent/AU5550800A/en
Publication of WO2000078934A2 publication Critical patent/WO2000078934A2/en
Publication of WO2000078934A3 publication Critical patent/WO2000078934A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A gene has been identified in human chromosomes, on human chromosome 21 in the region q11-q21. The gene has been sequenced and shown to have sequence homologies with the ubiquitin specific protease family. The recombinant gene has been cloned into E.coli, and the product shown to have ubiquitin specific protease properties. It is believed that the activity of the enzyme may be involved in the pathway leading to neurofibrillar tangles observed in Alzheimer's disease and/or in general neurotoxicity leading to progressive neuronal degeneration and cell death. The invention relates to processes for diagnosing Alzheimer's disease, for treating Alzheimer's disease and for investigating the mechanism of Alzheimer's disease. The sequence of the enzyme has GenBank accession No. AF 134213. The gene has the name USP25, approved by the HUGO Nomenclature Committee.
PCT/GB2000/002423 1999-06-22 2000-06-22 Use of the ubiquitin specific protease usp25 in the diagnosis and treatment of alzheimer's disease Ceased WO2000078934A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU55508/00A AU5550800A (en) 1999-06-22 2000-06-22 Diagnosis and treatment of alzheimer's disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9914589.8A GB9914589D0 (en) 1999-06-22 1999-06-22 Diagnosis and treatment of alzheimers diease
GB9914589.8 1999-06-22
GB0008162.0 2000-04-03
GB0008162A GB0008162D0 (en) 2000-04-03 2000-04-03 Diagnosis and treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
WO2000078934A2 WO2000078934A2 (en) 2000-12-28
WO2000078934A3 true WO2000078934A3 (en) 2001-07-05

Family

ID=26244029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002423 Ceased WO2000078934A2 (en) 1999-06-22 2000-06-22 Use of the ubiquitin specific protease usp25 in the diagnosis and treatment of alzheimer's disease

Country Status (2)

Country Link
AU (1) AU5550800A (en)
WO (1) WO2000078934A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506032A (en) * 1999-07-31 2003-02-18 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Centrin-specific human protease SENP1-3
US6709839B1 (en) * 1999-09-24 2004-03-23 Rigel Pharmaceuticals, Inc. SYK-UBP proteins, compositions and methods of use
JP2004500812A (en) * 1999-12-23 2004-01-15 インサイト・ゲノミックス・インコーポレイテッド Protease
US7122332B2 (en) * 2001-03-29 2006-10-17 Rigel Pharmaceuticals, Inc. Modulators of leukocyte activation, compositions and methods of use
EP1622420A3 (en) 2003-02-14 2009-11-25 Widex A/S A battery compartment for a hearing aid
US20050287121A1 (en) * 2004-05-12 2005-12-29 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
ATE524487T1 (en) * 2007-01-11 2011-09-15 Univ Ramot TAU PEPTIDE MIMETIC FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CN109071561B (en) 2016-02-12 2022-01-14 福马治疗股份有限公司 Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
US10913753B2 (en) 2016-02-12 2021-02-09 Valo Early Discovery, Inc. Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
US11524966B1 (en) 2017-08-11 2022-12-13 Valo Health, Inc. Carboxamides as ubiquitin-specific protease inhibitors
JP2021534122A (en) 2018-08-09 2021-12-09 ヴァロ アーリー ディスカバリー， インコーポレイテッド Inhibition of deubiquitinating enzymes USP25 and USP28
CA3108676A1 (en) 2018-08-09 2020-02-13 David J. Guerin Carboxamides as ubiquitin-specific protease inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046289A1 (en) * 1998-03-12 1999-09-16 Human Genome Sciences, Inc. 31 human secreted proteins
EP0972837A2 (en) * 1998-05-11 2000-01-19 Smithkline Beecham Plc Ubiquitin specific protease like protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046289A1 (en) * 1998-03-12 1999-09-16 Human Genome Sciences, Inc. 31 human secreted proteins
EP0972837A2 (en) * 1998-05-11 2000-01-19 Smithkline Beecham Plc Ubiquitin specific protease like protein

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
D'ANDREA ALAN ET AL: "Deubiquitinating enzymes: A new class of biological regulators.", CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 33, no. 5, October 1998 (1998-10-01), pages 337 - 352, XP000943354, ISSN: 1040-9238 *
DATABASE EMBL 24 June 1997 (1997-06-24), STRAUSBERG, R.: "Homo sapies cDNA clone IMAGE:824710 5' similar to SW:UBP2-YEAST Q01476 UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 2", XP002152574 *
DATABASE EMBL 29 November 1996 (1996-11-29), HILLIER, L. ET AL.: "Homo sapiens cDNA clone IMAGE:549350 5' similar to WP:K02C4.3 CE01599 UBIQUITIN CARBOXYL-TERMINAL HYDROLASE", XP002152573 *
GROET JUERGEN ET AL: "Bacteria contig map of the 21q11 region associated with Alzheimer's disease and abnormal myelopoiesis in Down syndrome.", GENOME RESEARCH, vol. 8, no. 4, April 1998 (1998-04-01), pages 385 - 398, XP000943367, ISSN: 1088-9051 *
GROET JURGEN ET AL: "Narrowing of the region of allelic loss in 21q11-21 in squamous non-small cell lung carcinoma and cloning of a novel ubiquitin-specific protease gene from the deleted segment.", GENES CHROMOSOMES & CANCER, vol. 27, no. 2, February 2000 (2000-02-01), pages 153 - 161, XP000943091, ISSN: 1045-2257 *
KATSANIS NICHOLAS ET AL: "Localisation of receptor interacting protein 140 (RIP140) within 100kb of D21S13 on 21q11, a gene-poor region of the human genome.", HUMAN GENETICS, vol. 102, no. 2, February 1998 (1998-02-01), pages 221 - 223, XP000943739, ISSN: 0340-6717 *
REEVES ROGER H ET AL: "A mouse model for Down syndrome exhibits learning and behaviour deficits.", NATURE GENETICS, vol. 11, no. 2, 1995, pages 177 - 184, XP000943482, ISSN: 1061-4036 *
VALERO REBECA ET AL: "USP25, a novel gene encoding a deubiquitinating enzyme, is located in the gene-poor region 21q11.2.", GENOMICS, vol. 62, no. 3, 15 December 1999 (1999-12-15), pages 395 - 405, XP002153277, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
WO2000078934A2 (en) 2000-12-28
AU5550800A (en) 2001-01-09

Similar Documents

Publication Publication Date Title
US5843641A (en) Methods for the daignosis, of familial amyotrophic lateral sclerosis
WO2000078934A3 (en) Use of the ubiquitin specific protease usp25 in the diagnosis and treatment of alzheimer's disease
Ketterer et al. Inherited diseases caused by mutations in cathepsin protease genes
WO2004027033A3 (en) Lentiviral vector-mediated gene transfer and uses thereof
JP6124943B2 (en) SAP variants and uses thereof
WO2001083782A3 (en) Novel proteases
WO2004076639A3 (en) Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
Langton et al. Sorsby's fundus dystrophy mutations impair turnover of TIMP-3 by retinal pigment epithelial cells
AU2002365646A1 (en) Novel proteins with il-6 inhibiting activity
Uhlemann et al. DNA phasing by TA dinucleotide microsatellite length determines in vitro and in vivo expression of the gp91phox subunit of NADPH oxidase and mediates protection against severe malaria
EP1343532A4 (en) Lentiviral vector-mediated gene transfer and uses thereof
WO2002074956A3 (en) Dopaminergic neuronal survival-promoting factors and uses thereof
CA2495529A1 (en) Noonan syndrome gene
Shibata et al. Disruption of structural and functional integrity of α2‐macroglobulin by cathepsin E
WO2001010893A3 (en) Il-16 antagonists
WO2004038026A3 (en) Calcineurin-like human phosphoesterase
WO2003097687A3 (en) Neuroprotective polypeptides and methods of use
WO2000079267A3 (en) Use of hte ubiquitin specific protease usp25 in the treatment, prophylaxis and diagnosis of cancer
WO2008099928A1 (en) Placental protein having action of regulating protease activity and its related gene
Zerovnik Human stefins and cystatins
WO2003074059A3 (en) Materials and methods relating to the treatment of lymphoma
EP1199372A3 (en) Polymorphisms in the human P2X7 gene
UA91178C2 (en) Mutated neublastin
EP0856583A3 (en) Protein rab3 GEP
US20090275033A1 (en) Uses of BNIPXL-Beta in premature canities

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP